Are all “moles” the same?

No. Lesions that patients describe as a “mole” may look similar but represent different types of skin lesion.

A melanocytic naevus, a raised intradermal naevus, a skin tag (acrochordon) or a seborrhoeic keratosis may appear similar to a patient. They are not the same structure, so they do not necessarily require the same method of removal.

The distinction matters for more than simply naming the lesion. Some lesions can be treated superficially, while others need to be removed in a way that preserves tissue for microscopic examination.

“Mole removal” is therefore not one single procedure.

What is the difference between destroying a lesion and removing it as tissue?

The key difference is whether a specimen remains available for examination afterwards.

With ablation, the target tissue is deliberately destroyed. There may be no intact specimen left to send for histopathological examination.

When a lesion is physically removed, all or part of the tissue is obtained as a specimen and can be examined microscopically when needed.

Both approaches may make the lesion no longer visible from the outside, but they do not provide the same diagnostic information. 12

Can the same device perform two different jobs?

Yes. Both CO₂ laser and radiofrequency can be used either to remove tissue from the surface by ablation or to cut tissue, depending on the technique. The name of the device therefore does not by itself describe what was done. 12

A superficial lesion can be ablated with radiofrequency. When radiofrequency is used in cutting mode, the lesion is physically separated; this is also referred to as RF cutting or radiosurgery. 1

For example, cutting a narrow-based skin tag with radiofrequency is different from ablating a superficial lesion with the same device. Even though the device is identical, the tissue left for subsequent examination may be different.

CO₂ laser is also not limited to ablation; with an appropriate technique it can be used as a cutting tool. 2

Physical removal of tissue does not automatically mean that every specimen will have the same histological quality. Thermal effects can make microscopic assessment of tissue edges more difficult, so technique becomes particularly important when surgical margins need to be interpreted. 3

How do the features of a lesion affect the choice of method?

Pigmentation, surface characteristics, elevation, depth, borders and anatomical location can all influence method selection.

A narrow-based superficial lesion and a naevus extending more deeply into the skin are not approached in the same way. In a pigmented lesion with diagnostic uncertainty, preserving tissue may become more important. 7

Anatomical location also affects the consequences of treatment. On the face, nose, eyelids, lips or ears, even a small tissue defect can influence the appearance of the scar or surrounding contour.

This is why the answer to “Can it be removed with laser?” or “Can it be removed with radiofrequency?” depends on more than whether a device is technically capable of removing it. The characteristics of the lesion and the result required from the procedure both matter.

Why does the method change when pathology is needed?

If tissue needs to be examined microscopically, a procedure that completely destroys the lesion may also destroy information that is needed for diagnosis. 567

Histopathological examination can establish the true type and cellular characteristics of a lesion and, in some situations, help assess the edges of the removed tissue. 567

Pathology is therefore not simply an administrative step considered after treatment. The possibility that tissue will need to be examined can affect which methods are appropriate from the beginning.

If diagnosis is uncertain or assessment of surgical margins is important, a method that preserves tissue is required. In selected clinically typical superficial lesions where a specimen is not needed, ablation may be one of the options.

There is no single rule that says every mole must, or must not, be sent to pathology. The decision depends on the lesion and the diagnostic information required.

Will mole or skin tag removal leave a scar?

Every procedure on the skin creates a healing area, but how visible it remains depends on the method, treatment depth, anatomical location and the individual’s healing response.

After superficial ablation, the result may involve redness, pigment change or a difference in surface texture rather than a linear incision. The appearance varies with treatment depth and individual healing.

Surgical removal usually creates a linear scar. In return, the lesion can be obtained as tissue and sent for histopathological examination when needed.

Choosing a method only by asking “Which leaves less of a scar?” is therefore incomplete. The more useful question is which healing pattern is acceptable while still achieving the treatment and diagnostic information the lesion requires.

Should multiple moles or skin tags all be treated in the same way?

No. Having many lesions does not mean that every lesion is the same type.

Among several similar skin tags or raised lesions, one lesion may have a different pigmentation, surface or structure and require separate assessment.

It is therefore not appropriate to assign every lesion to the same device or treatment method in advance.

What does it mean if a removed lesion appears again?

A lesion appearing again does not always represent true recurrence. Residual tissue after the original procedure or changes within the treated area can produce a similar appearance. 4

For example, if a melanocytic naevus is incompletely removed superficially, remaining naevus cells may later produce renewed pigmentation or elevation. This pattern is known as a recurrent naevus. 4

When pigmentation or a raised area develops again at a previously treated site, it is useful to know which method was used and to review any earlier pathology result.

Rather than automatically repeating the previous treatment, the first step is to establish what the new tissue represents.

When is it no longer a straightforward “mole removal”?

Clear change, repeated bleeding, ulceration, unusual pigmentation or diagnostic uncertainty means that establishing the diagnosis should take priority over simply choosing a cosmetic removal method. 567

These findings do not by themselves mean skin cancer. They change the priority from straightforward cosmetic removal to diagnostic assessment.

Basal cell carcinoma, cutaneous squamous cell carcinoma or melanoma may sometimes first be described by a patient as a “mole”, a “sore” or a repeatedly crusting lesion.

In this setting, preserving tissue, obtaining appropriate surgical margins and considering any necessary oncological assessment become important. A procedure that simply destroys the tissue can reduce information that may be needed later. 567

The main principle when choosing a method

The appropriate method for a skin lesion depends on what the lesion is, whether the tissue needs to be preserved and the expected pattern of healing — not simply on the name of the device.

Ablation and physical removal of tissue serve different purposes. The fact that CO₂ laser or radiofrequency is used does not by itself tell you whether the procedure was ablative or tissue-removing.

References

  1. Kaur RR, Glick JB, Siegel D. Achieving hemostasis in dermatology – Part 1. Indian Dermatology Online Journal. 2013;4(2):71–81. DOI: 10.4103/2229-5178.110575.
  2. Madan V. Dermatological Applications of Carbon Dioxide Laser. Journal of Cutaneous and Aesthetic Surgery. 2013;6(4):175–177. DOI: 10.4103/0974-2077.123393.
  3. Turner RJ, Cohen RA, Voet RL, Stephens SR, Weinstein SA. Analysis of tissue margins of cone biopsy specimens obtained with “cold knife,” CO2 and Nd:YAG lasers and a radiofrequency surgical unit. Journal of Reproductive Medicine. 1992;37(7):607–610.
  4. Okada MAMU, Heck R, Bakos RM. Histological and immunohistochemical findings in recurrent nevi. Anais Brasileiros de Dermatologia. 2025;100(6). DOI: 10.1016/j.abd.2025.501241.
  5. Peris K, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. European Journal of Cancer. 2023;192:113254. DOI: 10.1016/j.ejca.2023.113254.
  6. Stratigos AJ, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment—update 2026. European Journal of Cancer. 2026;243:116764. DOI: 10.1016/j.ejca.2026.116764.
  7. Amaral T, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2025;36(1):10–30. DOI: 10.1016/j.annonc.2024.11.006.